End Stage Renal Failure With Renal Transplant Clinical Trial
Official title:
Evaluation of the Early Conversion From a Calcineurin Inhibitor-based Immunosuppressive Regimen to Everolimus in de Novo Renal Transplant Recipients, a Multicenter Experience
In the present study, the investigators propose a conversion scheme with 50% reduction in
CNI dosage until adjustment of everolimus dosage, in order to reach a trough blood level of
6-10 ng/mL, thus avoiding overimmunosuppression or alternatively breakthrough rejection
episodes.
The hypothesis of this study is to demonstrate that the therapeutic regimen with Myfortic®
and Certican® significantly improves renal function compared with the standard regimen of
CNI.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03143556 -
Black Star - Magnetic Stent Removal in Transplant Patients
|
N/A | |
| Active, not recruiting |
NCT01413464 -
The Risk of Venous Clotting in Patients After Renal Transplant
|
N/A | |
| Recruiting |
NCT01285375 -
Safety and Preliminary Efficacy of the Treatment of Kidney Allografts With Curcumin-containing Preservation Solution
|
Phase 1 | |
| Completed |
NCT01653847 -
Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens
|
N/A |